Top researchers are discussing notable developments in neuroscience, including research in many neuromuscular diseases, at the annual American Academy of Neurology meeting April 21-28
Top scientists and clinicians from around the world are discussing the latest research in neuroscience, and the care of individuals with nerve and muscle diseases, at the 2012 annual meeting of the American Academy of Neurology in New Orleans, April 21-28.
Topics of discussion include: autoimmune diseases, cell biology, child neurology, diagnostic testing in neuromuscular disease, diseases of the peripheral nerves, disorders of the neuromuscular junction, genetics and gene therapy, motor neuron diseases, movement disorders, the muscular dystrophies and stem cells.
MDA is hosting a luncheon at the meeting for students and researchers interested in entering the field of neuromuscular disease research.
Updates on recent research and clinical trials will cover diseases, including: amyotrophic lateral sclerosis (ALS), Duchenne muscular dystrophy (DMD), facioscapulohumeral muscular dystrophy (FSHD), inflammatory myopathies, limb-girdle muscular dystrophy (LGMD),myasthenia gravis (MG), spinal muscular atrophy (SMA), mitochondrial myopathies, and other diseases in MDA’s program.
The updates include:
For more information on scheduled presentations and clinical trial updates, view the AAN’s 2012 Scientific Abstract Listing and Annual Meeting Information.
In addition to medical and scientific presentations, the annual AAN meeting is a place for working groups to move projects forward, for young professionals and students to find mentors, and for researchers to network and forge collaborations.
MDA is hosting a "mentor-mentee" luncheon on April 24 to introduce researchers and clinicians to MDA's training grants program. The grant program is designed to encourage and support new researchers entering the field of neuromuscular disease research.
Also at this year's meeting, clinicians involved with the National ALS Registry, a national database of information from patients and families with this disease, are scheduled to meet and discuss the status of this important project, sponsored by the U.S. Centers for Disease Control and Prevention.